Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Steroid treatment like Emflaza is considered standard of care and availability of other products may make payer discussions difficult.
You may also be interested in...
With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.
Insurer will begin excluding drugs when there are less expensive and clinically equivalent alternatives available and eliminate manufacturer coupons from the calculation of deductibles and out-of-pocket limits.
US FDA's Peripheral and Central Nervous System Drugs Advisory Committee to consider application, which PTC Therapeutics filed over protest.